| World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access |
| Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc |
| Journal website http://www.wjon.org |
Case Report
Volume 6, Number 1, February 2015, pages 311-315
Overview of Recent Trends in the Management of Metastatic Anal Cancer
Table
| Chemotherapy | Treatment | Prior treatment | Response | PFS (months) | OS (months) | KRAS status | Toxicity grade |
|---|---|---|---|---|---|---|---|
| 5-FU: 5-fluorouracil; NA: not available; NR: no response; PD: progressive disease; PFS: progression free survival; PR: partial response; OS: overall survival; SD: stable disease. | |||||||
| Cetuximab/irinotecan | First | NA | NR | 7 | 12 | WT | 2 |
| Cetuximab/irinotecan | First | NA | NR | 8 | 12 | WT | 1 |
| Cetuximab/irinotecan | First | NA | PD | 2 | 7 | G12V mutation | 0 |
| Cetuximab/irinotecan | First | NA | PD | 2 | 6 | G12V & D33D mutation | 0 |
| Cetuximab/irinotecan | Second | 5-FU, cisplatin | PR | 10 | 21 | WT | 2 |
| Cetuximab/irinotecan | Second | 5-FU, cisplatin | PR | 3.5 | NA | WT | 1 |
| Cetuximab/irinotecan | Third | Capecitabine, mitomycin C, vinorelbine | PR | 5 | 5 | ND | 1 |
| Paclitaxel | First | NA | PD | 2 | 7 | ||
| Paclitaxel | First | NA | PR | 4 | 12 | ||
| Paclitaxel | First | NA | SD | 4 | 6 | ||
| Paclitaxel | First | NA | CR | 8 | 14 | ||
| Paclitaxel | First | NA | PR | 6 | NA | ||
| Paclitaxel | First | NA | PD | 2 | 5 | ||
| Paclitaxel | First | NA | PR | NA | NA | ||